ORKA
Oruka Therapeutics, Inc.
$92.38
+0.73
(+0.80%)
Mkt Cap
5.58B
Volume
585,299
52W Range
14.67-115.52
Sector
Healthcare
Beta
-0.39
EPS (TTM)
-2.47 USD
P/E Ratio
-13.12
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (105.43M) | (83.72M) | (5.34M) | (9.93M) | (19.32M) | (9.74M) | (5.48M) | (7.93M) | (18.49M) | (16.44M) | (11.45M) | (9.69M) |
| EPS | -2.31 | -4.99 | -4.44 | -8.27 | -16.68 | -8.40 | -49.79 | -123.73 | -382.87 | -390.96 | -393.12 | -710.64 |
| Free Cash Flow | (88.42M) | (58.03M) | N/A | (10.91M) | (18.80M) | (7.74M) | (4.80M) | (8.25M) | (17.48M) | (15.00M) | (10.54M) | (9.43M) |
| FCF / Share | -1.94 | -3.46 | N/A | -0.76 | -1.35 | -1.64 | -43.64 | -128.64 | -361.85 | -357.31 | -362.16 | -695.11 |
| Operating CF | (88.21M) | (57.84M) | N/A | (10.91M) | (18.76M) | (7.72M) | (4.80M) | (8.24M) | (17.47M) | (14.99M) | (10.53M) | (9.41M) |
| Total Assets | 488.62M | 396.02M | 37.86M | 43.09M | 54.92M | 50.43M | 8.54M | 6.83M | 12.37M | 24.63M | 39.57M | 16.13M |
| Total Debt | 1.93M | 968,000 | 280,000 | 383,000 | 483,000 | 450,000 | 25,000 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 46.94M | 61.58M | 37.43M | 42.45M | 53.36M | 49.07M | 8.36M | 6.61M | 8.70M | 7.40M | 38.80M | 15.35M |
| Book Value | 471.93M | 382.22M | 37.02M | 41.67M | 51.04M | 46.52M | 7.61M | 6.03M | 10.28M | 22.19M | 38.07M | 14.74M |
| Return on Equity | -0.22 | -0.22 | -0.14 | -0.24 | -0.38 | -0.21 | -0.72 | -1.32 | -1.80 | -0.74 | -0.30 | -0.66 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (41.21M) | (31.82M) | (29.58M) | (30.28M) | (24.57M) | (21.00M) | (33.39M) | (28.62M) | (22.24M) | (2.01M) | (1.09M) | (1.42M) |
| EPS | -0.66 | -0.58 | -0.54 | -0.69 | -0.58 | -0.50 | -1.54 | -1.91 | -1.30 | -0.24 | -0.90 | -1.19 |
| Free Cash Flow | (33.15M) | (23.65M) | (22.66M) | (21.70M) | (23.18M) | (20.88M) | (18.84M) | (35.03M) | (2.63M) | (168,000) | N/A | N/A |
| FCF / Share | -0.53 | -0.43 | -0.42 | -0.49 | -0.55 | -0.50 | -1.12 | -2.33 | -0.18 | -0.01 | N/A | N/A |
| Operating CF | (33.15M) | (23.58M) | (22.59M) | (21.60M) | (23.14M) | (20.87M) | (18.82M) | (34.86M) | (2.63M) | (168,000) | N/A | N/A |
| Total Assets | 1.14B | 504.48M | 488.62M | 509.25M | 357.42M | 377.11M | 396.02M | 414.09M | 33.84M | 36.71M | 37.86M | 39.18M |
| Total Debt | 2.55M | 1.81M | 1.93M | 1.91M | 2.33M | 947,000 | 968,000 | 988,000 | 24,000 | 48,000 | 280,000 | 301,000 |
| Cash & Equiv | 268.47M | 49.52M | 46.94M | 91.25M | 65.40M | 83.57M | 61.58M | 410.88M | 33.28M | 35.90M | 37.43M | 38.49M |
| Book Value | 1.11B | 486.72M | 471.93M | 486.79M | 343.64M | 364.73M | 382.22M | 342.37M | 32.57M | 35.12M | 37.02M | 37.97M |
| Return on Equity | -0.04 | -0.07 | -0.06 | -0.06 | -0.07 | -0.06 | -0.09 | -0.08 | -0.68 | -0.06 | -0.03 | -0.04 |
ORKA News
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade